Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.
Company profile
Ticker
NVO, NONOF
Exchange
Website
CEO
Lars Fruergaard Joergensen
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
NVO stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
17 Apr 24
6-K
Current report (foreign)
17 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
Current report (foreign)
2 Apr 24
6-K
Current report (foreign)
1 Apr 24
6-K
Current report (foreign)
25 Mar 24
6-K
Current report (foreign)
21 Mar 24
6-K
Current report (foreign)
18 Mar 24
6-K
Current report (foreign)
11 Mar 24
6-K
Current report (foreign)
8 Mar 24
Latest ownership filings
SC 13G/A
BlackRock Inc.
6 Feb 24
11-K
Annual report of employee stock purchases
27 Jun 23
11-K
Annual report of employee stock purchases
27 Jun 23
SC 13G/A
BlackRock Inc.
23 Feb 23
11-K
Annual report of employee stock purchases
28 Jun 22
11-K
Annual report of employee stock purchases
28 Jun 22
SC 13G/A
BlackRock Inc.
1 Feb 22
11-K
Annual report of employee stock purchases
23 Jun 21
11-K
Annual report of employee stock purchases
23 Jun 21
SC 13G/A
BlackRock Inc.
29 Jan 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
7.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1239 |
Opened positions | 228 |
Closed positions | 268 |
Increased positions | 476 |
Reduced positions | 367 |
13F shares | Current |
---|---|
Total value | 21.64 tn |
Total shares | 246.27 mm |
Total puts | 504.88 k |
Total calls | 1.72 mm |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Jennison Associates | 22.53 mm | $2.33 tn |
Fisher Asset Management | 14.13 mm | $1.46 tn |
Renaissance Technologies | 13.85 mm | $1.43 bn |
FMR | 12.66 mm | $1.31 tn |
Fayez Sarofim & Co | 11.81 mm | $1.43 tn |
MS Morgan Stanley | 10.61 mm | $1.10 tn |
Loomis Sayles & Co L P | 9.00 mm | $931.39 mm |
Folketrygdfondet | 8.63 mm | $892.90 bn |
Polen Capital Management | 7.96 mm | $823.30 bn |
T. Rowe Price | 7.77 mm | $803.41 mm |
News
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
18 Apr 24
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
18 Apr 24
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
18 Apr 24
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $5,200 Today
15 Apr 24
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
12 Apr 24
Press releases
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
28 Mar 24
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
26 Mar 24
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
22 Mar 24
Thinking about trading options or stock in Apple, Pfizer, Taiwan Semiconductor, Microsoft, or Novo Nordisk?
12 Mar 24
Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity
8 Mar 24